Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ANPA | Rich Sparkle | $16.31 | -$10.24 | -38.57% | 35.2K | $203.9M | $2.80$54.75 |
| IMPP | Imperial Petroleum | $4.69 | -$1.31 | -21.83% | 3.7M | $163.4M | $2.12$6.57 |
| SGBX | Safe & Green | $3.26 | -$0.64 | -16.41% | 3.2M | $18.5M | $1.81$122.88 |
| LEDS | SemiLEDs | $2.02 | -$0.39 | -16.04% | 91.7K | $16.6M | $1.20$3.37 |
| AGCC | Agencia Comercial Spirits | $6.10 | -$1.07 | -14.92% | 100.8K | $208.1M | $3.66$8.25 |
| LINK | Interlink Electronics | $3.62 | -$0.53 | -12.77% | 120.7K | $57.0M | $2.94$10.10 |
| BUUU | Buuu Group | $7.05 | -$0.97 | -12.10% | 3.7K | $117.6M | $3.67$9.50 |
| AEHL | Antelope Enterprise | $3.09 | -$0.38 | -10.95% | 863.7K | $10.6M | $1.13$11.53 |
| SONN | Sonnet BioTherapeutics | $3.72 | -$0.44 | -10.47% | 418.4K | $26.3M | $1.08$19.30 |
| IONZ | Tidal Trust II - Defiance Daily Target 2x Short Ionq ETF | $4.13 | -$0.46 | -10.02% | 10.6M | - | $2.08$22.95 |
Related Articles
Featured Article
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Alex Carchidi|Jun 12, 2023
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.
3 No-Brainer Stocks to Buy Right Now for Less Than $25
James Halley|Feb 4, 2023
All three healthcare stocks are showing solid long-term potential.
3 Great Stocks Under $10
Will Healy|Sep 27, 2020
These stocks hold tremendous potential despite a low price.
Is Ironwood Pharmaceuticals Stock a Buy?
David Jagielski, CPA|Feb 12, 2020
The stock is down year to date, but a strong fourth-quarter performance could quickly turn things around.
Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know
Keith Speights|Jul 31, 2019
The drugmaker delivered its first-ever quarterly profit and trounced Wall Street top- and bottom-line estimates.
Novartis May Beat Ironwood Pharmaceuticals to the Punch
Todd Campbell|Oct 30, 2018
Novartis may be on track to win FDA approval of a sickle disease drug before Ironwood.
A David and Goliath Story: Can Small-Cap Synergy Pharmaceuticals Take on Ironwood Pharmaceuticals?
David Liang|Jan 5, 2017
Has the success of Synergy Pharmaceuticals' plecanatide put Ironwood on the warpath?
